silybin

Silybin A is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.

Silybin B (Silibinin B) is an effective inhibitor of raloxifene 4 '- and 6-glucosalylation, an effective anti-fibrinogenic and anti-oligomeric component of Silymarin, with free radical scavenging activity of 1, 1-diphenyl-2-pyridinyl hydrazine (DPPH), and a protective effect against cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. Silybin B can inhibit the growth of human chronic myeloid leukemia K562 cells and induce apoptosis.

(±)-Silybin is the racemate of Silybin and has antioxidant properties, with an IC25 value of 61.4 μM in the DPPH experiment.

Silybin is a flavonoid from Silybum that inhibits P-glycoprotein-assisted extracellular efflux, inhibits cytochrome P450 enzymes, has the advantage of being well-tolerated, can be used as an adjunctive treatment for hepatotoxicity and chronic hepatitis and cirrhosis, and has antioxidant and anti-inflammatory activity in cosmetic applications, as well as being capable of blocking the MCT8 transporter protein.

Silymarin is a natural polyphenolic flavonolignan mixture extracted from the seeds of Silybum marianum. It can inhibit tumor cell proliferation and angiogenesis, and improve insulin resistance, thus being widely used in liver disease-related research and adjuvant applications. Studies have shown that silymarin exhibits inhibitory activity against the SARS-CoV-2 main protease, and it has potential research value in the mechanism-related studies of COVID-19.

Silibinin-D3 is the deuterium-labelled compound of silibinin, used for isotope tracing. Silibinin (T1660) is the primary active component of milk thistle, capable of inhibiting cancer cell proliferation and migration.

Silibinin (Standard) is a reference standard for research and analysis in studies involving Silibinin. Silibinin (Silybin) is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.

Silybin B (Standard) is a reference standard for research and analysis in studies involving Silybin B. Silybin B (Silibinin B) is an effective inhibitor of raloxifene 4 '- and 6-glucosalylation, an effective anti-fibrinogenic and anti-oligomeric component of Silymarin, with free radical scavenging activity of 1, 1-diphenyl-2-pyridinyl hydrazine (DPPH), and a protective effect against cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. Silybin B can inhibit the growth of human chronic myeloid leukemia K562 cells and induce apoptosis.

Isosilybin (Isosilibinin) and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.

Isosilybin (Standard) is a reference standard for research and analysis in studies involving Isosilybin. Isosilybin (Isosilibinin) and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.

2,3-Dehydrosilybin A (catalog number: T125202) is a valuable organic compound for life sciences research.

2,3-Dehydrosilybin B is a useful organic compound for research related to life sciences and the catalog number is T125883.

2,3-Dehydrosilybin A (Standard) is a reference standard for research and analysis in studies involving 2,3-Dehydrosilybin A. 2,3-Dehydrosilybin A is a useful organic compound for research related to life sciences and the catalog number is T125202.

2,3-Dehydrosilybin B (Standard) is a reference standard for research and analysis in studies involving 2,3-Dehydrosilybin B. 2,3-Dehydrosilybin B is a useful organic compound for research related to life sciences and the catalog number is T125883.

Isosilybin B (Standard) is a reference standard for research and analysis in studies involving Isosilybin B. Isosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.

Isosilybin A is a partial PPARγ agonist, it significantly induced ABCA1 protein expression, it inhibited both monophenolase (IC50=1.7-7.6μM) and diphenolase (IC50=12.1-44.9μM) of tyrosinase. Isosilybin A shows anti-angiogenic efficacy, it has anti-prostate cancer (PCA) activity that is mediated via cell cycle arrest and apoptosis induction.

Isosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.

m-PEG4-Tos, a PEG-based PROTAC linker derived from silybin ethers, finds application in the synthesis of Silymarin[1].

m-PEG5-Tos is a PEG-based PROTAC linker derived from silybin ethers. This compound serves as an essential component in the synthesis of Silymarin[1].

Tos-PEG8-m, a PEG-based PROTAC linker, is a derivative of silybin ethers. It is utilized in the synthesis of Silymarin[1].

FASN/SCD-IN-1 is a Silybin derivative and an orally active inhibitor of fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In vitro, FASN/SCD-IN-1 demonstrates the ability to inhibit lipid deposition, reduce the transcription levels of FASN and SCD, and exhibits antioxidant, anti-inflammatory, and antifibrotic activities. It shows significant hepatoprotective effects in rat models of acute liver injury and improves pathological features such as steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative-associated steatohepatitis (MASH). FASN/SCD-IN-1 can be used for MASH research.

Torilin and torilolone show hepatoprotective effects on tacrine-induced cytotoxicity in human liver-derived Hep G2 cells,the EC50 values are 20.6 +/- 1.86 and 3.6 +/- 0.1 microM, respectively; and silybin as a positive control shows an EC50 value of 69.0